President's Message - Jul 2014 - What Is New in Heart Failure? Reflections from Athens ESC-HF Meeting

Written by President
Monday, 07 July 2014

The European Society of Cardiology (ESC) heart failure meeting was held in Athens, Greece during the period 17-20 May this year. This was possibly the largest and the most important heart failure scientific event. More than 50 topics were discussed from molecular biology to artificial heart and assist devices. In the following massage, I will briefly review some of the sessions, which I attended during the meeting, covering: new drugs, biomarkers, new imaging techniques, heart failure with preserved EF, heart failure with CAD, diabetes, renal dysfunction and psychosocial disorders.


President's Message - Apr 2014 - Aldosterone and Aldosterone Antagonists: Current and Future Directions

Written by President
Friday, 04 April 2014

Aldosterone receptor antagonists (ARAs) are gaining increasing importance in the management of patients with high blood pressure and heart failure. Ongoing research is exploring further therapeutic indications for this pharmacologic group. The molecular basis of aldosterone mechanism of action were defined many years ago and its pleotropic effects were identified. The following message reviews the physiology of aldosterone, its potential harmful effects, the current and possible future therapeutic potentials of ARAs.


President's Message - Jan 2014 - Resistant Hypertension Revisited

Written by President
Tuesday, 31 December 2013

Resistant hypertension, through uncommon in routine daily practice and in general population, its prevalence is high in specialized hypertension clinics and in clinical trials. In ALLHAT, CONVINCEm LIFE and INSIGHT, blood pressure was not reduced to target levels of < 140/90 mmHg in 30 to 50% of patients. Resistant hypertension is defined as failure to achieve adequate blood pressure control within 3 months in spite of a concomitant use of three or more antihypertensive drugs including a diuretic. Another definition is blood pressure greater than 160/100 mmHg on two visits not less than 2 months apart in spite of triple antihypertensive therapy which should include diuretics, beta blockers, sympatholytic and a vasodialator, ACE- inhibitors, ARB or calcium antagonist.


User Login

No account yet? Create account
EHS Fans Corner

Who's online

We have 21 guests online